-
Dusetzina SB. Characterizing and assessing antiemetic underuse in patients initiating highly emetogenic chemotherapy. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2019 Mar 26.
Abstract
Patients initiating highly emetic chemotherapy (HEC) are at a 90% risk of chemotherapy-induced nausea and vomiting (CINV). Despite guideline-concordant antiemetic prescribing preventing CINV in up to 80% of patients, studies suggest that guideline-concordant antiemetic regimen use by patients initiating HEC is sub-optimal. However, these studies have been limited to single-site or single-cancer type with limited generalizability. The objective of this study was to describe antiemetic fill regimens and to assess predictors of underuse in the USA.